Advertisement
| financial help with humira: Living with Rheumatoid Arthritis Tammi L. Shlotzhauer, 2014-09 Describes new findings about the causes and treatments for rheumatoid arthritis, offering strategies for dealing with the chronic illness. |
| financial help with humira: Making Medicines Affordable National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Care Services, Committee on Ensuring Patient Access to Affordable Drug Therapies, 2018-03-01 Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€and health care at largeâ€more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€coupled with the broader trends in overall health care costsâ€is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care. |
| financial help with humira: Biosimilars and Interchangeable Biologics Sarfaraz K. Niazi, 2018-10-30 What’s the Deal with Biosimilars? Biosimilars are gaining momentum as new protein therapeutic candidates that can help fill a vital need in the healthcare industry. The biological drugs are produced by recombinant DNA technology that allows for large-scale production and an overall reduction time in costs and development. Part of a two-volume set that covers varying aspects of biosimilars, Biosimilars and Interchangeable Biologics: Strategic Elements explores the strategic planning side of biosimilar drugs and targets issues surrounding biosimilars that are linked to legal matters. This includes principal patents and intellectual property, regulatory pathways, and concerns about affordability on a global scale. It addresses the complexity of biosimilar products, and it discusses the utilization of biosimilars and related biological drugs in expanding world markets. Of specific interest to practitioners, researchers, and scientists in the biopharmaceutical industry, this volume examines the science, technology, finance, legality, ethics, and politics of biosimilar drugs. It considers strategic planning elements that include an overall understanding of the history and the current status of the art and science of biosimilars, and it provides detailed descriptions of the legal, regulatory, and commercial characteristics. The book also presents a global strategy on how to build, take to market, and manage the next generation of biosimilars throughout their life cycle. |
| financial help with humira: Kiplinger's Personal Finance , 2007-12 The most trustworthy source of information available today on savings and investments, taxes, money management, home ownership and many other personal finance topics. |
| financial help with humira: Curbside Consultation in IBD David T. Rubin, Sonia Friedman, Francis A. Farraye, 2024-06-01 Newly updated with the latest information on inflammatory bowel disease, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition contains brief, practical, and evidence-based answers to the most frequently asked questions that are posed during a “curbside consultation” between surgical colleagues. Drs. David T. Rubin, Sonia Friedman, and Francis A. Farraye are joined by an expert group of contributors, offering advice, preferences, and opinions on tough clinical questions commonly associated with IBD. With a unique Q&A format, this text provides quick access to current information. Numerous images, diagrams, and references are included to better illustrate IBD. Some of the questions answered inside the Third Edition include: What are the new approaches to using and minimizing steroids? What is the evolving role of calcineurin inhibitors in IBD? Where should anti-IL-23 therapy be placed in the therapeutic algorithm for Crohn’s disease and ulcerative colitis? What should the clinicians and patients know about biosimilars? What are JAK inhibitors? And when should they be used in IBD? What is the approach to loss of response to biological therapy? How should we screen our patients with IBD for depression and anxiety? With information basic enough for trainees and expert practical advice that even high-volume clinicians will appreciate, Curbside Consultation in IBD: 49 Clinical Questions, Third Edition is a must-have. Gastroenterologists, surgeons, IBD nurses and advanced practice providers, and medical and surgical trainees at all levels will benefit from the user-friendly format and up-to-date advice for complicated cases. |
| financial help with humira: The Role of NIH in Drug Development Innovation and Its Impact on Patient Access National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, 2020-01-27 To explore the role of the National Institutes of Health (NIH) in innovative drug development and its impact on patient access, the Board on Health Care Services and the Board on Health Sciences Policy of the National Academies jointly hosted a public workshop on July 24â€25, 2019, in Washington, DC. Workshop speakers and participants discussed the ways in which federal investments in biomedical research are translated into innovative therapies and considered approaches to ensure that the public has affordable access to the resulting new drugs. This publication summarizes the presentations and discussions from the workshop. |
| financial help with humira: Healthcare Finance Andrew W. Lo, Shomesh E. Chaudhuri, 2022-11-15 Why healthcare finance? -- From the laboratory to the patient -- Present value relations -- Evaluating business opportunities -- Valuing bonds -- Valuing stocks -- Portfolio management and the cost of capital -- Therapeutic development and clinical trials -- Decision trees and real options -- Monte Carlo simulation -- Healthcare analytics -- Biotech venture capital -- Securitizing biomedical assets -- Pricing, value, and ethics -- Epilogue : a case study pf royalty pharma. |
| financial help with humira: Managed Entry Agreements and Funding for Expensive Therapies Mondher Toumi, Szymon Jarosławski, 2022-06-24 Market entry agreements (MEA) for pharmaceuticals have become extremely popular and widespread geographically. Emerging countries that have not yet begun to introduce MEAs are now actively engaged in doing so. This book examines the concept of MEAs, detailing how depreciation of some specific regenerative therapies through intangible asset amortization is unavoidable. The authors provide a historical vision of the development of MEAs with experiences, failures, and successes that have shaped the evolution and place of MEAs in access to pharmaceuticals. They provide an extensive review of MEA typology and propose a new one that is pragmatic and actionable. FEATURES Discusses the affordability of future therapies and the possible challenges for health insurance systems Addresses the practical and applied issue of market access and includes the most up-to-date developments, such as the Pelosi bill Describes the potential paradigm change that will challenge all payers and may question the sustainability of our health care systems Highlights the gradual move from repeated treatment administration to a single administration with the potential for a definite cure Managed Entry Agreements and Funding for Expensive Therapies provides invaluable information to all stakeholders involved in market access and to students in the field. |
| financial help with humira: Consumer Knowledge and Financial Decisions Douglas J. Lamdin, 2011-11-23 There has been an increasing recognition that financial knowledge (i.e., literacy) is lacking across the population. Moreover, there is recognition that this lack of knowledge poses real problems as credit, mortgages, health insurance, retirement benefits, and savings and investment decisions become increasingly complex. Financial Decisions Across the Lifespan brings together the work of scholars from various disciplines (family and consumer sciences, economics, law, finance, sociology, and public policy) to provide a broad range of perspectives on financial knowledge, financial decisions, and policies. For consistency across the volume each chapter follows a similar format: (1) what individuals know or need to know (2) how what they know or need to know affects financial decisions and outcomes (3) ways in which policies or programs or financial innovations can enhance their knowledge, or decisions, or outcomes. Contributors will provide both new and existing research to create a valuable picture of the state of financial literacy and how it can be improved. |
| financial help with humira: Rare Diseases and Orphan Products Institute of Medicine, Board on Health Sciences Policy, Committee on Accelerating Rare Diseases Research and Orphan Product Development, 2011-04-03 Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development. |
| financial help with humira: Smart Buys Drug-Wise Lee Brian Haak, Rick Melcher, Deborah S. Romaine, 2004-12-07 Tells how you can save 25% to 75% --sometimes even more--on almost all the drugs you buy without risking your health or safety. |
| financial help with humira: The Transformation of American Health Insurance Troyen A. Brennan, 2024-07-30 Can American health insurance survive? In The Transformation of American Health Insurance, Troyen A. Brennan traces the historical evolution of public and private health insurance in the United States from the first Blue Cross plans in the late 1930s to reforms under the Biden administration. In analyzing this evolution, he finds long-term trends that form the basis for his central argument: that employer-sponsored insurance is becoming unsustainably expensive, and Medicare for All will emerge as the sole source of health insurance over the next two decades. After thirty years of leadership in health care and academia, Brennan argues that Medicare for All could act as a single-payer program or become a government-regulated program of competing health plans, like today's Medicare Advantage. The choice between these two options will depend on how private insurers adapt and behave in today's changing health policy environment. This critical evolution in the system of financing health care is important to employers, health insurance executives, government officials, and health care providers who are grappling with difficult strategic choices. It is equally important to all Americans as they face an inscrutable health insurance system and wonder what the future might hold for them regarding affordable coverage. |
| financial help with humira: Reading Between the Lines of Corporate Financial Reports Jacek Welc, 2020-11-28 This book provides a digestible step-by-step guide to reading corporate financial reports, drawing upon real-life case studies and examples of corporate collapses and accounting scandals, and applying practical tools to financial statement analysis. Appealing to a range of practitioners within corporate finance including investors, managers, and business analysts, this book is the first to specifically address the challenges facing those who are not professional accountants and auditors when examining corporate financial reports. Corporate financial reports are used widely by managers, investors, creditors, and government agencies to examine company performance and evaluate potential risks. However, although seemingly an invaluable source of information for managerial decision-making, financial reports are often based on rough simplifications of a very complex reality. With no way of avoiding deliberate manipulations and fraudulent activity, these statements cannot be relied on completely when selecting stocks or evaluating credit risk, and therefore poor analysis can lead to potentially disastrous investment decisions. The author suggests that in order to effectively interpret corporate financial reports, we must 'read between the lines' to accurately assess a company's economic performance and predict its long-term viability. |
| financial help with humira: Government, Big Pharma, and The People Mickey Smith, 2020-12-02 Pharmaceuticals constitute a relatively small share of the total Health Care expenditure in most developed economies, and yet they play a critical role in the ongoing debate over how best to advance, improve, and afford Health Care. Despite this, and perhaps because of this, the industry has had, for many years, an outsized claim to fame and controversy, praise and criticisms, and support and condemnation. Unfortunately, many participants in the debate do not fully understand the complexities of the industry and its role in the overall Health Care system. The analytical tools of economics provide a strong foundation for a better understanding of the dynamics of the pharmaceutical industry, its contribution to Health and Health Care, and its dual and often conflicting priorities of affordability and innovation, as well as the various Private and Public Policy initiatives directed at the sector. Everyone is affected by Big Pharma and the products they produce. At the Drug store, the physician’s office, in front of the television, in everyday conversations, Drugs are a part of our lives. Society shapes our values toward Drugs and Drugs shape society. (The Pill and minor tranquilizers are good examples.) And, of course, the way Congress deliberates and Big Pharma responds has a huge impact on how Drugs affect our lives. This book is well-researched on the subject of the pharmaceutical industry, its struggles with Government, and its relationship to the consumer from the early twentieth century until the present. The Dynamic Tension between the three participants – Government, Big Pharma, and the People – is described and explained to lead to an understanding of the controversies that rage today. The author describes how the Government, its many investigatory efforts, and the ultimate legislative results affect the industry and the consequences of their activities are explored in light of their effects on other players, including the patients and consumers who rely on both Government and Big Pharma for their well-being and who find sometimes unexpected consequences while giving special attention to the attitudes, beliefs, and misadventures of less-than-optimal Drug use. Stakeholders are identified with physicians as a major focus, as well as describing the significance of prescriptions as social objects and the processes by which physicians make choices on behalf of their patients. The author ties it all together with how Big Pharma affects and is affected by each of these groups. The author utilizes his 50-plus years’ experience as an academic, practicing pharmacist, and Big Pharma employee to describe the scope of the pharmaceutical industry and how it affects us on a daily basis, concluding with an inside look at Big Pharma and how regulations, marketing, and the press have affected their business, both good and bad. |
| financial help with humira: The Business of Healthcare Innovation Lawton Robert Burns, 2005-08-25 The Business of Healthcare Innovation is the first wide-ranging analysis of business trends in the manufacturing segment of the health care industry. In this leading edge volume, Professor Burns focuses on the key role of the 'producers' as the main source of innovation in health systems. Written by professors of the Wharton School and industry executives, this book provides a detailed overview of the pharmaceutical, biotechnology, genomics/proteomics, medical device and information technology sectors. It analyses the market structures of these sectors as well as the business models and corporate strategies of firms operating within them. Most importantly, the book describes the growing convergence between these sectors and the need for executives in one sector to increasingly draw upon trends in the others. It will be essential reading for students and researchers in the field of health management, and of great interest to strategy scholars, industry practitioners and management consultants. |
| financial help with humira: Kiplinger's Personal Finance , 2009-05 |
| financial help with humira: Kiplinger's Personal Finance , 2009-08 The most trustworthy source of information available today on savings and investments, taxes, money management, home ownership and many other personal finance topics. |
| financial help with humira: Kiplinger's Personal Finance , 2007-11 The most trustworthy source of information available today on savings and investments, taxes, money management, home ownership and many other personal finance topics. |
| financial help with humira: Ferri's Clinical Advisor 2021 Fred F. Ferri, 2020-06-10 Find fast answers to inform your daily diagnosis and treatment decisions! Ferri’s Clinical Advisor 2021 uses the popular 5 books in 1 format to deliver vast amounts of information in a clinically relevant, user-friendly manner. This bestselling reference has been significantly updated to provide you with easy access to answers on 1,000 common medical conditions, including diseases and disorders, differential diagnoses, clinical algorithms, laboratory tests, and clinical practice guidelines—all carefully reviewed by experts in key clinical fields. Extensive algorithms, along with hundreds of new figures and tables, ensure that you stay current with today's medical practice. Contains significant updates throughout, covering all aspects of current diagnosis and treatment. Features 27 all-new topics including chronic rhinosinusitis, subclinical brain infarction, reflux-cough syndrome, radiation pneumonitis, catatonia, end-stage renal disease, and genitourinary syndrome of menopause, among others. Includes new appendices covering common herbs in integrated medicine and herbal activities against pain and chronic diseases; palliative care; and preoperative evaluation. Offers online access to Patient Teaching Guides in both English and Spanish. |
| financial help with humira: Global Innovation and Economic Value Vijay Kumar, R. P. Sundarraj, 2018-01-28 This book attempts to capture innovation outcomes. The intent is on a holistic assessment of value creation by innovation — the societal value that it delivers to humanity, the economic value that it has the potential to endow to nations, and the monetary value that it provides to innovating firms. With a range of anecdotal examples and empirical analysis, the book endeavours to answer the question: Have investments in innovation paid off? Big data and analytics underpin the development of the book material. The coverage is truly global, accentuating the economic value created by innovation in the technology and pharmaceutical sectors, the two largest bastions of innovation. In addition, it includes numerous examples of successful innovation in global companies while analyzing its economic/financial impact. |
| financial help with humira: Oxford Textbook of Rheumatoid Arthritis David L. Scott, James Galloway, Andrew Cope, Arthur Pratt, Vibeke Strand, 2020-09-18 This brand new textbook of rheumatoid arthritis (RA) is an important addition to the Oxford Textbooks in Rheumatology series, and provides a comprehensive overview of both the scientific and clinical aspects of the disease. Divided into eight sections - from the history, diagnosis, and epidemiology of the disease, through the pathogenesis, clinical presentation, and assessment to treatments and management strategies, both drug- and non-drug based - each chapter is written by leading clinicians and scientists in the field to deliver a contemporary view of RA. During the past two decades there have been revolutionary changes in the understanding and management of rheumatoid arthritis, in particular the development of biological treatments. This has had wide-ranging effects on almost all aspects of treatment, from effectiveness and intensity to the nature and the cost. Providing a comprehensive account of the modern ideas about the disease, the Oxford Textbook of Rheumatoid Arthritis is a key new addition to the literature, with each chapter providing a detailed background, key recent advances, and areas of doubt and future developments. Featuring over 170 photographs, radiological images, and clinical charts to aid both diagnosis and illustrate the rationale behind key scientific studies, this new title will prove an indispensable resource for specialist rheumatologists, trainees in rheumatology, and other members of the multi-disciplinary team. |
| financial help with humira: The Core Model Ibis Sanchez Serrano, 2019-06-04 The Core Model: A Collaborative Paradigm for the Pharmaceutical Industry and Global Health Care develops the innovative core model, an organizational research and design paradigm and economic theory that proposes a collaborative approach to resolving global health issues and improving the productivity of drug development. The model proposes that scientific collaboration does not occur in an unstructured manner, but actually takes place within a highly structured order where knowledge is transferred, integrated and finally translated into commercial products. An understanding of this model will help solve the global pharmaceutical industry ́s productivity problems and address important global health care and economic issues. This book is useful to researchers, advanced students, regulators, and management in pharmaceutical industries, as well as healthcare professionals, those working in health economics, and those interested in scientific innovation processes. - Explores the current state-of-the-art in the pharmaceutical industry and the global healthcare sector - Includes insights from world-leading figures in the pharmaceutical industry, healthcare sector, federal funding agencies, regulatory bodies, investment sector, entrepreneurship, intellectual property law, philanthropic organizations, and advocacy groups - Develops in-depth, original concepts, which have important implications in the understanding of, and search for, potential solutions to the world ́s health care crisis |
| financial help with humira: Born With a Junk Food Deficiency Martha Rosenberg, 2012-04-10 This hard-hitting exposé blows the lid off of everything you thought you knew about Big Pharma and Big Food. What goes on behind the scenes in these industries is more suspicious, more devious, more disreputable than you could have ever imagined. Rosenberg’s message is clear: the pharmaceutical and agricultural industries are tainting public health through marketing disguised as medical education and research, aggressive lobbying, and high-level conflicts of interest. If you’re concerned about the safety of the drugs you take and the food you eat, you owe it to yourself to read this important book. Having gained the trust of more than twenty doctors, researchers, and experts who were willing to come forward and finally tell all, reporter and editorial cartoonist Rosenberg presents us with her shocking findings. Explosive material from whistle-blowers, scientists, unsealed lawsuits, and Big Pharma’s and Big Food’s own marketers exposes how these industries put profits before public safety and how the government puts the interests of business before the welfare of consumers, creating a double whammy that pimps the public health. What Rosenberg reveals about government complicity, regulatory food- and drug-safety lapses, and legislative injustices will both shock and appall. |
| financial help with humira: Sex and Gender Differences in Pharmacology Vera Regitz-Zagrosek, 2012-10-02 This is the very first book to deal with sex and gender differences in drug therapy - an increasingly recognized medical need. It starts with an overview on S/G in clinical syndromes and a documentation of the medical and socioeconomic damage caused by gender specific adverse drug effects. Part I covers S/G differences in pharmacokinetics. Researchers will be satisfied by the detailed discussion of the mechanisms of S/G differences in drug effects that represents cutting edge science and includes interaction of drugs with sex hormones, genomic and epigenetic mechanisms. It also covers S/G in drug development, in animal models and clinical development and S/G in drug prescriptions. Part II targets S/G differences in drug effects in cardiovascular, pulmonary, CNS, neuromuscular, neuropsychiatric and metabolic diseases, in cancer, inflammation, and rheumatic diseases, in bacterial and retroviral infections, thrombosis, embolism. New drugs will be discussed. |
| financial help with humira: Iron Empires Michael A. Hiltzik, 2020 From Pulitzer Prize-winner Michael Hiltzik, the epic tale of the clash for supremacy between America's railroad titans. |
| financial help with humira: The Right Price Peter J. Neumann, Joshua T. Cohen, Daniel A. Ollendorf, 2021-05-06 The US prescription drug business is a $500 billion industry whose rising prices carry profound consequences for patients, caregivers, employers and taxpayers across the nation. In the United States, average prices of leading brand-name drugs are two to four times higher than prices charged in other wealthy countries, raising questions as to what Americans are getting for the extra expense. On the other hand, healthy industry returns have arguably fueled life-saving innovation. With the advent of ever more targeted and powerful treatments, including cell- and gene-based therapies with multi-million-dollar price tags, the need for sensible drug pricing policies will only intensify. The Right Price sheds light on the controversial topic of drug pricing by providing an accessible guide to pharmaceutical markets and analytic techniques used to measure the value of drug therapies. It illustrates the need for value-based pricing through real-life stories of patients and their experiences with the drug industry and explains why simple solutions like price controls and the importation of cheaper drugs from other countries are problematic. This volume describes how researchers and policy makers have pursued drug valuation efforts in the past, and lays out a series of recommendations, based on years of shared author experience serving on national drug policy platforms, for how to further improve pharmaceutical value assessment in the United States. With unique industry insights and clear narrative, The Right Price unveils why the pricing of drugs continues to be so challenging and how public and private officials can create more informed policies to achieve the right balance between drug pricing and value. |
| financial help with humira: Treatment of Non-infectious Uveitis Phoebe Lin, Eric Suhler, 2019-09-12 This unique, comprehensive book provides a much-needed reference on the treatment and management of non-infectious uveitis. Carefully designed, Treatment of Non-infectious Uveitis is the first book of its kind to provide an in-depth, clinically-relevant, expert-driven resource for ophthalmologists focusing on modalities of uveitis treatment, their mechanism of action, dosing, and side effects. Each chapter provides an introduction, mechanism of action, indication, dosage, side effects, and efficacy summaries from clinical trials and other published literature. Topics range from topical treatment, to locally administered therapy including drug-releasing implants, to systemic immunosuppressive treatments both tried and new, as well as surgical management, with each chapter highlighting important practice pearls as well as easy-reference dosing tables, side effects, and lab monitoring pertinent to the agents discussed. The book concludes with a discussion of novel approaches to the treatment of non-infectious uveitis, and special considerations when treating uveitis in the pediatric patient. The majority of patients with non-infectious uveitis are treated by comprehensive ophthalmologists, many of whom are less familiar with established treatment guidelines outlining the role of corticosteroids and immunomodulatory therapy. While the non-specialist, resident, or fellow is sure to benefit from this one-stop guide to uveitis treatment, retina and uveitis specialists alike will also appreciate the practice tips and thorough coverage of this expertly-written reference. Treatment of Non-infectious Uveitis is the ideal reference for all ophthalmologists who seek to improve their understanding of the causes of uveitis and learn how to best treat this condition. |
| financial help with humira: Invest Diva’s Guide to Making Money in Forex: How to Profit in the World’s Largest Market Kiana Danial, 2013-07-05 Q: Ladies, Do YOU Have What It Takes To Become A Forex Diva? A: Yes, You Do. With this incredible new step-by-step guide, investing pro and TV personality Kiana Danial shows you exactly how to understand and take advantage of foreign currency trading. Years ago, the author discovered that women in Japan were making a fortune trading currencies on the foreign exchange (forex) market. These ladies were not investment professionals or financial wizards; they were ordinary individuals who simply learned how the online currency exchange market works--and mastered it. Now you can do the same. In fact, you're about to see just how easy it can be to trade on the largest and most liquid financial market in the world. Kiana Danial spent years studying the habits of investors and discovered that women frequently make smarter, wiser, and less-risky investment choices than their male counterparts. This is precisely why she founded InvestDiva.com--the woman's guide to smart, safe, and profitable trading. By tapping into women's intuitive knack for multitasking and risk management, the author demonstrates why a woman's natural skill sets make her uniquely equipped to reap the enormous rewards of this extremely lucrative field. Invest Diva will show you: How the global currency market works Why social, political, and cultural events shape trading The smartest short- and long-term strategies Best practices for navigating the economic calendar Plus, you'll learn how to identify investment opportunities and spot trends using the five points of the Invest Diva Diamond: * Technical Analysis * Fundamental Analysis * Sentimental Analysis * Capital Analysis * Overall Analysis From her popular blog to her worldwide TV and web presence, Danial has become famous for making complex topics fun and easy to understand via simple, everyday analogies. With Invest Diva, she shows women everywhere the stress-free way to trade currencies--without ever leaving home. What the Boys of Wall Street don't want you to know . . . After years of studying the principles of the foreign currency exchange market, financial expert and financial correspondent Kiana Danial gets to the bottom of today's most curious investment phenomenon: Why are women suddenly making a fortune trading currencies? The answer is inside this book, along with a roadmap designed to show you how and why forex can work for you. Kiana Danial breaks down a sophisticated foreign exchange market with memorable analogies that can help the most financially illiterate person understand and gain passion in following the markets the way Ms. Danial does. -- FAN YANG, CMT, CEO, FXTimes.com A must-read if you're considering trading any market or need to know more about trading the forex market. Kiana is an experienced market analyst and a gifted communicator whose book confirms what a lot of men are coming to realize--that women have an edge in trading because they understand the value of analyzing and planning before they risk their time and money. -- JAY NORRIS, founder, Trading University, and author of Mastering the Currency Market and Mastering Trade Selection and Management |
| financial help with humira: Valuations of Early-Stage Companies and Disruptive Technologies Tiran Rothman, 2020-11-27 This book will serve as a practical guide for entrepreneurs and investors/advisors in constructing and understanding valuations of startups in rapidly shifting industries, including the areas of drug development, medical devices, cyber security, and renewable energy. For large companies, valuation is based on forecasts of free cash flow; in technologically-driven industries, product pipelines can represent a large part of market capitalization. The situation is even more critical for small companies committed to a single idea: all of their value is linked to a single project. Any business transaction or internal proposal to begin or terminate an R&D project in which innovative projects are being valued or exchanged requires a realistic valuation of those projects. Moreover, different projects have very different dynamics. Pharmaceuticals have very large lead times and are dependent on patents as well as out-licensing agreements. In contrast, software develops very quickly, and IP is hard to value. This book will be a guide to building appropriate valuations for companies competing in rapidly shifting industries and offering products under new business models where little precedent exists, taking both financial and behavioral issues into consideration. |
| financial help with humira: The 100 Best Stocks to Buy in 2020 Peter Sander, Scott Bobo, 2019-12-10 The 2020 edition of the 100 Best Stocks series picks the top stocks for you to buy based on authors Peter Sander and Scott Bobo’s value-investing philosophy, the same philosophy followed by Warren Buffett. Even though the economy is in constant flux, there are still plenty of opportunities for smart investors to make a profit. The 100 Best Stocks to Buy in 2020 demonstrates how to protect your money with stock picks that have consistently performed. In their easy-to-understand and highly practical language, authors Peter Sander and Scott Bobo clearly explain their value-investing philosophy, as well as offer low-volatility investing tips and advice to finding stocks that consistently perform and pay dividends. The 100 Best Stocks to Buy in 2020 is an essential guidebook for anyone looking to invest in today’s market providing a proven source of solid, dependable advice you can take to the bank. |
| financial help with humira: Pediatric Inflammatory Bowel Disease Petar Mamula, Jonathan E. Markowitz, Robert N. Baldassano, 2012-12-14 Pediatric Inflammatory Bowel Disease, Second Edition provides an essential reference with an emphasis on the unique pediatric issues of IBD. Chapters focus on complications of IBD specific to children and adolescents. Treatment recommendations are based on the latest clinical research available. The textbook also presents sections dedicated to the aspects of participation in clinical research unique to children and adolescents and the complicated yet vital process of successfully transitioning a patient from a pediatric to adult specialist. Controversies in pediatric IBD care such as the off-label use of medications are also covered. The format incorporates multiple tables, graphs, and figures to improve readability and make for an efficient reference for clinicians to use. Thoroughly revised and updated from the first edition, the volumes includes new therapies that are currently being used or tested for treatment of IBD, important areas regarding incidence and prevalence, immunization and response to vaccine administration as well as advancements in our understanding of growth and development with particular to the use of growth hormone therapy. Other new areas covered include important topics of complementary and alternative medicine use in IBD, immunization, and liver disease in IBD. Pediatric Inflammatory Bowel Disease, Second Edition is a valuable resource for pediatric gastroenterologists as well as adult gastroenterologists. |
| financial help with humira: The Privatization of Everything Donald Cohen, Allen Mikaelian, 2021-11-23 The book the American Prospect calls “an essential resource for future reformers on how not to govern,” by America’s leading defender of the public interest and a bestselling historian “An essential read for those who want to fight the assault on public goods and the commons.” —Naomi Klein A sweeping exposé of the ways in which private interests strip public goods of their power and diminish democracy, the hardcover edition of The Privatization of Everything elicited a wide spectrum of praise: Kirkus Reviews hailed it as “a strong, economics-based argument for restoring the boundaries between public goods and private gains,” Literary Hub featured the book on a Best Nonfiction list, calling it “a far-reaching, comprehensible, and necessary book,” and Publishers Weekly dubbed it a “persuasive takedown of the idea that the private sector knows best.” From Diane Ravitch (“an important new book about the dangers of privatization”) to Heather McGhee (“a well-researched call to action”), the rave reviews mirror the expansive nature of the book itself, covering the impact of privatization on every aspect of our lives, from water and trash collection to the justice system and the military. Cohen and Mikaelian also demonstrate how citizens can—and are—wresting back what is ours: A Montana city took back its water infrastructure after finding that they could do it better and cheaper. Colorado towns fought back well-funded campaigns to preserve telecom monopolies and hamstring public broadband. A motivated lawyer fought all the way to the Supreme Court after the state of Georgia erected privatized paywalls around its legal code. “Enlightening and sobering” (Rosanne Cash), The Privatization of Everything connects the dots across a wide range of issues and offers what Cash calls “a progressive voice with a firm eye on justice [that] can carefully parse out complex issues for those of us who take pride in citizenship.” |
| financial help with humira: Health Promotion Throughout the Life Span - E-Book Carole Edelman, Elizabeth C. Kudzma, 2021-11-12 Health Promotion Throughout the Life Span - E-Book |
| financial help with humira: Science, the State and the City Geoffrey Owen, Michael M. Hopkins, 2016-04-15 The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation ecosystem, and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries. |
| financial help with humira: From Breakthrough to Blockbuster Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos, 2022 Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive-- |
| financial help with humira: Plunkett's Biotech & Genetics Industry Almanac Jack W. Plunkett, 2008-09 A complete market research guide to the business of biotech, genetics, proteomics and related services--a tool for strategic planning, competitive intelligence, employment searches, or financial research. Complete profiles of nearly 400 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology--as well a addresses, phone numbers, and executive names. |
| financial help with humira: I Bytes Healthcare Industry ITshades.com, 2021-02-23 This document brings together a set of latest data points and publicly available information relevant for Healthcare Industry. We are very excited to share this content and believe that readers will benefit from this periodic publication immensely. |
| financial help with humira: The 100 Best Stocks You Can Buy 2010 Peter Sander, John Slatter, 2009-09-18 “Never invest in a company you don’t understand.”- Warren Buffett With Wall Street in shambles, investors need all the help they can get. There’s money to be made, but how? In this classic bestselling guide, Peter Sander and John Slatter offer informed, detailed advice about which stocks to buy in a time of financial chaos—and why. The 2010 edition of this classic guide features a new introduction discussing the current recession and how investors should cope with it as well as new stock picks and an updated listing of all recommended stocks by growth potential. Regardless of the economic climate, this guide remains the go-to guide for investors who want their money to work for them. |
| financial help with humira: Drugs, Money, and Secret Handshakes Robin Feldman, 2023-10-31 Examines the pharmaceutical industry to expose how higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. |
| financial help with humira: Business Development for the Biotechnology and Pharmaceutical Industry Martin Austin, 2016-04-08 Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world. |
Yahoo Finance - Stock Market Live, Quotes, Business & Finance …
Encouraging economic data has boosted market hopes for Fed rate cuts, but policymakers remain cautious. Trump's tariff timeout is almost up. Here's what could happen next.
Stock Market Prices, Real-time Quotes & Business News - Google
Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions.
Home Page - APG Federal Credit Union
APGFCU offers checking, savings, loans, and business banking services in Maryland to help you achieve your financial goals.
Stock Markets, Business News, Financials, Earnings - CNBC
Global Business and Financial News, Stock Quotes, and Market Data and Analysis. CNBC is the world leader in business news and real-time financial market coverage. Find fast, actionable...
MarketWatch: Stock Market News - Financial News
Americans spend $10 billion more on Mother’s Day than Father’s Day. What’s going on? So your company offered you a buyout. Should you take it? Here’s what to know. Hate paying so much …
Home - First Financial Federal Credit Union
Since 1953, First Financial Federal Credit Union has been strengthening the community through volunteering, donations, and financial education. Banking made easy. We’re your partner in …
Magnum Advisors - CPA Financial Services
Trust Magnum Advisors for expert financial services. Our CPAs offer personal and business tax solutions for connection, clarity, and confidence.
Financial Times
Planning your retirement? ChatGPT can help with that.
Branch Locations Near You - OneMain Financial
Find the closest OneMain Financial branch near you to talk to a real person. Get branch hours, directions, and phone numbers for our over 1,500 locations today.
Fidelity Investments - Retirement Plans, Investing, Brokerage, …
Manage your own investments (stocks, ETFs, mutual funds, CDs, and more), with help from our free resources. With a Fidelity Roth IRA, you get the flexibility to save for retirement, while …
Yahoo Finance - Stock Market Live, Quotes, Business & Finance …
Encouraging economic data has boosted market hopes for Fed rate cuts, but policymakers remain cautious. Trump's tariff timeout is almost up. Here's what could happen next.
Stock Market Prices, Real-time Quotes & Business News - Google
Google Finance provides real-time market quotes, international exchanges, up-to-date financial news, and analytics to help you make more informed trading and investment decisions.
Home Page - APG Federal Credit Union
APGFCU offers checking, savings, loans, and business banking services in Maryland to help you achieve your financial goals.
Stock Markets, Business News, Financials, Earnings - CNBC
Global Business and Financial News, Stock Quotes, and Market Data and Analysis. CNBC is the world leader in business news and real-time financial market coverage. Find fast, actionable...
MarketWatch: Stock Market News - Financial News
Americans spend $10 billion more on Mother’s Day than Father’s Day. What’s going on? So your company offered you a buyout. Should you take it? Here’s what to know. Hate paying so much …
Home - First Financial Federal Credit Union
Since 1953, First Financial Federal Credit Union has been strengthening the community through volunteering, donations, and financial education. Banking made easy. We’re your partner in …
Magnum Advisors - CPA Financial Services
Trust Magnum Advisors for expert financial services. Our CPAs offer personal and business tax solutions for connection, clarity, and confidence.
Financial Times
Planning your retirement? ChatGPT can help with that.
Branch Locations Near You - OneMain Financial
Find the closest OneMain Financial branch near you to talk to a real person. Get branch hours, directions, and phone numbers for our over 1,500 locations today.
Fidelity Investments - Retirement Plans, Investing, Brokerage, …
Manage your own investments (stocks, ETFs, mutual funds, CDs, and more), with help from our free resources. With a Fidelity Roth IRA, you get the flexibility to save for retirement, while …
